Aim: Infants with moderate or severe hemophilia in Asia: health-related life quality, immediate medical and social expenses. Methods: The Hemophilia Utilization Group Studies Part Vb acquired analysis of changes from ten US hemophilia treatment clinics from May 2020 to April 2021. Individuals having HB answered preliminary questionnaires on sociodemographic, clinical features, and society that treats. Participants indicated bleeding episodes, job absence, and caregiver time quarterly throughout a 2-year period. These figures were used to compute ABR and indirect expenses. Direct expenses were determined utilizing medical chart information dating back one year and pharmacy records dating back two years. Results: 119 of the 175 respondents had comprehensive medical records and one or more follow-up surveys. Total average yearly per individual expenses for mild/moderate HB were $87,856 (median $21,170), $197,737 (median$148,892) for extreme HB, and $5,140,250 (median$63,617) for all individuals without inhibitor (P o 0.0001). The mean ABR for patients with severe HB receiving prophylaxis (5.5 7.9 bleeds/y) remained nearly half than that of those managed episodically. Clotting expenditures accounted for 87% of overall prices, while indirect costs accounted for 11%. Prophylaxis use was connected to 2.6-fold higher clotting factor costs (P value 0.02), lower but substantially more missed familial workdays (P o 0.0002) and physician (P o 0.002) or nursing visits (P o 0.0001), less part-time employment and unemployment, and lesser hospitalization costs (P 14 0.18) and ABR (P value 0.0002). Conclusion: The substantial economic burden of HB is mostly due to clotting factor expenses. Nonetheless, prophylaxis therapy has therapeutic advantages and may lower relevant costs. Keywords: severe hemophilia, Asia, Moderate Hemophilia, Infants.